Neurizon Therapeutics Limited · ASX:NUZ
Neurizon Therapeutics — PharmAust — Investor Presentation (March 2015)
35 slides from Neurizon Therapeutics's investor presentation, March 2015
Slide 1: Shareholder Presentation March 2015
Shareholder For personal use only Presentation March 2015 ASX: PAA ACN 094 006 023
Slide 2: Disclaimer
DISCLAIMER For personal use only • This presenta,on does not cons,tute investment advice. Neither this presenta,on nor the informa,on contained in it cons,tutes an offer, invita,on , solicita,on or recommenda,on in rela,on to the purchase or sale of shares. • Shareholders should not rely on this pres
Slide 3: PharmAust Limited
PHARMAUST LIMITED For personal use only …Fast tracking leading edge technology in cancer therapy….
Slide 4: PharmAust Cancer Programs
PharmAust Cancer Programs For personal use only
Slide 5: Corporate Structure
PHARMAUST LIMITED CORPORATE STRUCTURE For personal use only PHARMAUST LIMITED ASX:PAA 100% 100% Sydney-‐Based Perth-‐Based
Slide 6: Challenging Limitations in Cancer Therapy
PharmAust -‐> Challenging Limita,ons in Cancer Therapy For personal use only • Drug Toxicity • Drug Resistance • Cancer Recurrence • Poor Tumour Targe,ng • Poor Diagnosis -‐> Pa,ents Progressed at Treatment • Op,mising Treatment • Survival vs Quality of Life
Slide 7: PharmAust Strategy
PHARMAUST STRATEGY 1. A Cancer focused Company For personal use only 2. Capitalising on over 10 years of research and development at the St George Hospital, Sydney 3. Capitalising on substan,ve investments by Major Pharmaceu,cal Corpora,ons 4. Focusing on new uses of exis,ng approved drugs 5. Crea,n
Slide 8: PharmAust Strategy
PHARMAUST STRATEGY For personal use only Oncology Focus • Targeting oncology applications of well established drugs and piggy-backing on substantive programmes of major pharmaceutical companies Leading New Drug for Cancer • Identifying highly specific clinical needs in Management oncology • Engaging
Slide 9: Targeted Therapies for Cancer
Targeted Therapies for Cancer For personal use only Recent Examples of New Targeted Therapies DRUG TARGET PEAK PATIENT COMPANY ANNUAL COST SALES HERCEPTIN + BREAST CANCER $6.5Bln $60,000/ GENENTECH/ PACLITAXEL (HER2-‐NEU) ANNUM ROCHE GLEEVEC MULTIPLE CANCERS $4.7Bln $92,000/ NOVARTIS TYROSINE KINAS
Slide 10: Foundations, Relationships and Commercial Cornerstones
Pharmaust Limited Foundations, Relationships and Commercial Cornerstones For personal use only Strategic IP -‐ Granted and Alliances Pending Patents NOVARTIS UNIVERSITY OF ANIMAL HEALTH CAMBRIDGE NEW SOUTHWALES Listed Japanese INNOVATIONS Group Royal Adelaide Hospital THE ST. GEORGE HOSPITAL S CMAX
Slide 11: St George Hospital Department of Surgery/Oncology
For personal use only St George Hospital Department of Surgery/Oncology
Slide 12: Monepantel (MPL)
MONEPANTEL (MPL) For personal use only 1. MPL is a new class of an,cancer drug 2. MPL can act alone or in combina,on with standard of care chemotherapy for treatment of cancer 3. Pharmaust has the IP for MPL assigned from the University of NSW
Slide 13: Monepantel's Unique Properties
MONEPANTEL’S UNIQUE PROPERTIES v Unlike most cancer drugs, MPL has virtually no toxicity based on the For personal use only toxicology undertaken by Novar,s Animal Health. MPL is currently sold as a treatment for sheep helminthic parasi,c infec,ons (Zolvix). Such treated animals enter the food chai
Slide 14: Monepantel Kills Drug-Resistant Cancer Cells
Monepantel Kills Drug-‐Resistant Cancer Cells For personal use only • Temozolamide resistant cancer cells are effec,vely killed by MPL • MPL has liole toxicity on “Normal” Human Embryonic Kidney Cells • MPL offers Treatment Op,ons either singularly or with “Standard of Care”
Slide 15: Effect of MPL on Cancer Cells
EFFECT OF MPL ON CANCER CELLS TEMOZOLAMIDE RESISTANT GLIOMA U251 TEMOZOLAMIDE RESISTANT GLIOMA U251 For personal use only Cell Proliferation (% of Control) 100 75 50 25 0 0 5 10 25 50 [MPL] (µM) NORMAL CELLS HEK [Human Embyonic Kidney cells] 100 Viability (%) 75 50 25 0 0 10 25 50 Monepantel [µM] PH
Slide 16: Effect of MPL on Tumour-Bearing Mice
EFFECT OF MPL ON TUMOUR-BEARING MICE For personal use only Dose-finding study of IP administered Drug in nude mice bearing Subcutaneous ovarian tumors (OVCAR-3), SC / IP Control Group Low dose Group High dose group VEHICLE MPL (25 mg/kg) MPL (50 mg/kg) DRUG DRUG
Slide 17: Synergy Between Aminoacetonitriles and Cytotoxic Drugs
SYNERGY BETWEEN AMINOACETONITRILES AND CYTOTOXIC DRUGS For personal use only • Selec,ve Synergy between MPL and cytotoxic drugs on “cancer” cells • Liole synergy between MPL and cytotoxic drugs on “normal” cells • Opportunity for “New Class” of drug for cancer • Therapy in conjunc,on with standard c
Slide 18: Enhancement of Doxorubicin and Gemcitabine
Enhancement of Doxorubicin and Gemcitabine For personal use only A 2 7 8 0 c e lls , 7 2 h tre a tm e n t w ith M P L & D o x o ru b ic in C ontrol M PL 50 m g/kg S R B a ss a y G em 2 m g/kg 150 G em 5 m g/kg 500 G em 2 m g/kg+ M PL 50 m g/kg ) 3 G em 5 m g/kg+ M PL 50 m g/kg (m m 100 400 % a liv e
Slide 19: Lack of Toxicity Measured by Weight Loss
Lack of PPL-‐1 Toxicity as OVCAR 3 S.C tumour; i.p. injection Measured by Weight Loss For personal use only B o d y W e ig h t 21 C o n tro l 2 m g /k g G e m 2 m g / k g G e m + 2 5 m g /k g M P L 20 A n im a l w e ig h t ( g ) 5 m g / k g G e m + 2 5 m g /k g M P L 5 m g /k g G e m 19 2 m g /k g
Slide 20: Synergy with Taxol
Synergy with Taxol For personal use only C o n tro l M P L 2 5 m g /k g M P L 5 0 m g /k g T a x o l 2 .5 m g /k g T a x o l 2 .5 m g /k g + M P L 2 5 m g /k g T a x o l 2 .5 m g /k g + M P L 5 0 m g /k g T a x o l 5 m g /k g T a x o l 5 m g /k g + M P L 2 5 m g /k g T u m o r v o lu m e (m m ) T a
Slide 21: Human Safety Trial - Monepantel
Human Safety Trial -‐ Monepantel For personal use only ACCELERATED ENTRY INTO MAN DUE TO EXTENSIVE TOXICOLOGY BY GLOBAL MAJOR – Pa,ent #1 -‐> 28 Day Completed (5mg/kg) with no adverse events; requested to con,nue on drug aper day 28 and CT Scan showed “Stable Disease”. Further subsequent tes,ng sh
Slide 22: PK and P70S6K (Preliminary Results)
PK AND P70S6K (Preliminary Results) For personal use only MPLS, R101 MPLS, R02 MPLS. Average 100% 69% 82% P70S6K p<0.017 350 DAY 0 3 7 300 Plasma ConcentraTon (ng/mL) 250 200 150 100 50 0 0 7 14 21 28 Study Day
Slide 23: Canine Trial
Canine Trial No Adverse Events Noted For personal use only • Four Dogs Received MPL (25mg/kg) compassionately • Three Dogs treated with the lowest dose of MPL (25mg/kg) as part of trial Tasteless Formula,on of MPL in Sop-‐ Gel Capsules
Slide 24: Albendazole for the Treatment of Ascites
Albendazole for the Treatment of Ascites For personal use only Two Clinical Trials Completed Showing: 1. Maximum tolerated dose 2. Benefits in Localised Therapy in the abdomen 3. Significant Inhibi,on of VEGF
Slide 25: Albendazole Ascites I
Albendazole Ascites I For personal use only IC50 = 1860μM
Slide 26: Ascites in Man
For personal use only Ascites in Man
Slide 27: Retention of Albendazole in the Abdomen
bdomen For personal use only 1.2 Reten,on of Albendazole in the Abdomen Albendazole concentraTon (mg/ml) 1 0.8 0.6 i.p Oral 0.4 0.2 0 0 0.25 1 2 4 8 12 16 24 30 48 72 120 Time a]er drug administraTon (h) Tumour Growing in the Abdomen and producing large quan,,es of Ascites fluid which distends the ab
Slide 28: Mucin Dissolution
Mucin Dissolu,on For personal use only Efficacy of a Novel Mucoly,c Agent on Pseudomyxoma Peritonei Mucin with Poten,al for Treatment through Peritoneal Catheters
Slide 29: About Epichem
About Epichem For personal use only l Formed in 2003 l Wholly owned subsidiary of PharmAust Ltd l Exper,se in synthe,c & medicinal chemistry l 17 Employees (16 BSc, 12 PhD) l Laboratories in Perth & Melbourne
Slide 30: Our Business
Our Business For personal use only l Contract research (fee-‐for-‐service) – predominantly for the drug discovery sector l Collabora,ve research (IP genera,on) – with partners with exper,se and assets in biology l Manufacture reference standards – predominantly for the pharmaceu,cal sector – ra
Slide 31: World Class - Globally Competitive
World Class -‐ Globally Compe,,ve For personal use only Perth Melbourne customers in 32 countries
Slide 32: Export Awards 2010-2013
Export Awards 2010-‐2013 For personal use only
Slide 33: Prospects for Contract Research Business
Prospects for Contract Research Business For personal use only l Global market for chemistry outsourcing is US$11bn – ...and growing at 10.5% p.a. l Australian sector recovering following GFC l The falling AUD and Epichem's growing reputa,on opens new opportuni,es in overseas markets l Revenues
Slide 34: Prospects for Reference Standards Business
Prospects for Reference Standards Business For personal use only l Global market > US$1bn p.a. l Highly fragmented market with 2 major suppliers – USP sales of ~US$140M p.a. – LGC sales of ~US$110M p.a. l Significant market growth due to: – ever increasing regulatory requirements – new & improved
Slide 35: Contact Details
Contact Details For personal use only DR ROGER ASTON Executive Chairman PharmAust Limited Email: rogeraston@pharmaust.com Phone: 61 (0) 402 762 204